User menu

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

Bibliographic reference Coiffier, Bertrand ; Radford, John ; Bosly, André ; Martinelli, Giovanni ; Barca, Gabriela ; et. al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. In: British Journal of Haematology, Vol. 163, no. 3, p. 334-342 (2013)
Permanent URL http://hdl.handle.net/2078.1/134669
  1. Armitage J. O., How I treat patients with diffuse large B-cell lymphoma, 10.1182/blood-2007-01-041871
  2. Cheson Bruce D., Pfistner Beate, Juweid Malik E., Gascoyne Randy D., Specht Lena, Horning Sandra J., Coiffier Bertrand, Fisher Richard I., Hagenbeek Anton, Zucca Emanuele, Rosen Steven T., Stroobants Sigrid, Lister T. Andrew, Hoppe Richard T., Dreyling Martin, Tobinai Kensei, Vose Julie M., Connors Joseph M., Federico Massimo, Diehl Volker, Revised Response Criteria for Malignant Lymphoma, 10.1200/jco.2006.09.2403
  3. Cillessen, Blood (ASH Annual Meeting Abstracts), 110, 2346 (2007)
  4. Coiffier, Blood, 92, 1927 (1998)
  5. Coiffier Bertrand, Lepage Eric, Brière Josette, Herbrecht Raoul, Tilly Hervé, Bouabdallah Reda, Morel Pierre, Van Den Neste Eric, Salles Gilles, Gaulard Philippe, Reyes Felix, Lederlin Pierre, Gisselbrecht Christian, CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, 10.1056/nejmoa011795
  6. Czuczman M. S., Fayad L., Delwail V., Cartron G., Jacobsen E., Kuliczkowski K., Link B. K., Pinter-Brown L., Radford J., Hellmann A., Gallop-Evans E., DiRienzo C. G., Goldstein N., Gupta I., Jewell R. C., Lin T. S., Lisby S., Schultz M., Russell C. A., Hagenbeek A., , Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study, 10.1182/blood-2011-09-378323
  7. Czuczman Myron S., Hess Georg, Gadeberg Ole V., Pedersen Lars M., Goldstein Nancy, Gupta Ira, Jewell Roxanne C., Lin Thomas S., Lisby Steen, Strange Claus, Windfeld Kristian, Viardot Andreas, , Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma, 10.1111/j.1365-2141.2012.09086.x
  8. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B., Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, 10.1200/jco.2005.09.131
  9. Hagenbeek A., Gadeberg O., Johnson P., Moller Pedersen L., Walewski J., Hellmann A., Link B. K., Robak T., Wojtukiewicz M., Pfreundschuh M., Kneba M., Engert A., Sonneveld P., Flensburg M., Petersen J., Losic N., Radford J., First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial, 10.1182/blood-2007-10-117671
  10. Matasar, Blood (ASH Annual Meeting Abstracts), 118, 957 (2011)
  11. Morton L. M., Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001, 10.1182/blood-2005-06-2508
  12. Muller C., Murawski N., Wiesen M. H. J., Held G., Poeschel V., Zeynalova S., Wenger M., Nickenig C., Peter N., Lengfelder E., Metzner B., Rixecker T., Zwick C., Pfreundschuh M., Reiser M., The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL, 10.1182/blood-2011-09-380949
  13. Smith A, Howell D, Patmore R, Jack A, Roman E, Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network, 10.1038/bjc.2011.450
  14. Teeling J. L., Mackus W. J. M., Wiegman L. J. J. M., van den Brakel J. H. N., Beers S. A., French R. R., van Meerten T., Ebeling S., Vink T., Slootstra J. W., Parren P. W. H. I., Glennie M. J., van de Winkel J. G. J., The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, 10.4049/jimmunol.177.1.362
  15. The Non-Hodgkin's Lymphoma Classification Project, Blood, 89, 3909 (1997)
  16. Vellenga E., van Putten W. L. J., van 't Veer M. B., Zijlstra J. M., Fibbe W. E., van Oers M. H. J., Verdonck L. F., Wijermans P. W., van Imhoff G. W., Lugtenburg P. J., Huijgens P. C., Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial, 10.1182/blood-2007-08-108415
  17. Wierda William G., Kipps Thomas J., Mayer Jiří, Stilgenbauer Stephan, Williams Cathy D., Hellmann Andrzej, Robak Tadeusz, Furman Richard R., Hillmen Peter, Trneny Marek, Dyer Martin J.S., Padmanabhan Swami, Piotrowska Magdalena, Kozak Tomas, Chan Geoffrey, Davis Randy, Losic Nedjad, Wilms Joris, Russell Charlotte A., Österborg Anders, Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia, 10.1200/jco.2009.25.3187
  18. Wierda W. G., Padmanabhan S., Chan G. W., Gupta I. V., Lisby S., Osterborg A., , Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study, 10.1182/blood-2011-04-348656